Adocia announces patenting GLP-1 amylin combination.

• Adocia has filed patent applications of stable combinations of semaglutide in combination with cagrilintide
• BioChaperone® CagriSema could be administered with all standard subcutaneous injection devices, particularly those for multi-use
• The selected BioChaperone® has already been tested in humans, has a regulatory dossier for entry into Phase 3, and is produced on a large scale in GMP-quality

Read the press release